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Diogo da Silva Miguel, Paulo Castro Chaves 
Cardiac adaptations to exercise: the role of stem cells and future therapeutic 
insights 
 
Abstract 
The heart responds to physical exercise through changes in its morphology known as 
physiological hypertrophy. Besides cardiomyocyte hypertrophy, there is also an 
increased cellular proliferation with formation of new myocytes. Altogether, these 
changes lead to an improvement in cardiac function. The molecular mechanism 
responsible for the development of physiological hypertrophy is centred in the IGF-
1R/PI3K/Akt signalling pathway, which modulates the activity of transcription factors 
involved in protein synthesis and cardiomyocytes proliferation. The endogenous pool of 
cardiac stem cells is believed to be crucial for the continuous renewal and regenerative 
potential of cardiac tissue, and has also been positively correlated with physiological 
hypertrophy. Another system involved in myocardium physiology and pathology is 
microRNA. The knowledge of the mechanisms underlying the beneficial effects of 
physical exercise over cardiac function may sustain the development of new therapeutic 
approaches regarding cardiac pathologies, which represent today an important cause of 
morbidity and mortality worldwide. 
 
Keywords: Exercise, Heart, Hypertrophy, microRNA, Stem cells.  
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Introduction 
The understanding of heart’s physiology has always been on the top of scientific 
community’s priorities. Indeed, there is an enormous amount of work available 
regarding this area of knowledge. 
The heart responds to increased workload with hypertrophy. According to the nature of 
the stimulus, the hypertrophy can be either physiological or pathological1. The main 
stimulus that leads to pathological hypertrophy is pressure overload, where the heart 
responds with hypertrophy of existing myocytes as an attempt to overwhelm the 
increased load2. However, in this setting maladaptive changes, such as apoptosis, 
necrosis and a shift in gene expression, also occur, which leads to rapid decline in 
cardiac function, with heart failure as possible outcome1, 2. In the opposite side there is 
the physiological hypertrophy, with physical exercise appearing as the best example of 
this type of cardiac adaptation. Unlike pressure overload, exercise training increases the 
blood flow through the heart (volume overload)1, which in turn results in lengthening of 
myocytes and consequent eccentric hypertrophy of the whole organ2. The normal 
structure of the myocardium is kept, the cardiac function remains unchanged or may 
improve3, and the loss of myocytes and increased fibrosis observed in pathological 
hypertrophy are actually attenuated with exercise training4.  
As noted above, physical exercise is the main trigger of physiological hypertrophy, with 
all the resulting benefits. Exercise training is today extensively prescribed and is a cheap 
and effective way for both the prevention and management of heart diseases3. Indeed, 
current evidence points that an improved fitness level is a strong indicator of freedom 
from all-cause mortality5 and is enough to decrease the morbidity and mortality linked 
with cardiac disorders6. Besides, physical exercise has been shown to protect the 
myocardium from age induced apoptosis, fibrosis and senescence4, 7, 8.  
4 
 
Until the past decade, it was believed that the heart was a post-mitotic organ, with no 
regenerative potential. However, an increasing body of evidence supports the existence 
of a resident population of cardiac stem cells9-12. This endogenous pool not only 
reassures the continuous renewal of cardiac tissue13, but also supports some grade of 
regeneration after an injury9, 11. The old paradigm of the heart as a terminally 
differentiated organ without any renewal potential did not give space for the exploration 
of regenerative medicine. However, by the light of the evidence accumulated during the 
past decade some work begun to be done in the field of regenerative medicine applied to 
the heart. 
This review aims to look over the mechanisms known to take part in the control of the 
adaptations of myocardium to physical exercise, and open new perspectives about 
possible applications of this knowledge in the search of new therapeutic approaches. 
 
Macroscopic and functional changes 
In 1975 Morganroth et al. used echocardiography to describe for the first time the 
cardiac changes induced by physical exercise, concluding that endurance exercise 
induced an increase in left ventricle mass and diastolic cavity size, while the wall 
thickness remained normal (eccentric hypertrophy). On the other hand, athletes that 
went through a resistance training program showed increased myocardial mass with 
ventricular wall thickening, but with normal diastolic cavity size (concentric 
hypertrophy)14. This concept has been accepted for decades as the “Morganroth 
hypothesis”. Indeed, other studies have found an increase in both left ventricular mass 
and left ventricle end diastolic diameter with endurance exercise15-17, though some of 
them have failed to show any effect of resistance training in cardiac morphology15, 16. 
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Adaptations at cellular level 
Unlike the macroscopic remodelling described in the previous paragraph, due to ethical 
limitations there is a paucity of studies describing the changes that occur at the cellular 
level in humans. However, a vast amount of studies using mice have shown that an 
increase in individual cardiomyocyte dimensions occurs in response to several 
swimming training programmes18-20. That increase comprises both the cardiomyocyte’s 
long and short axis and mean cell area21, and is remarkably related with the exercise’s 
intensity – high intensity exercise induces bigger changes than moderate intensity6. On 
the other hand, the pattern of cardiomyocyte growth is also determined by the type of 
physical exercise: while endurance training (swimming, running), and the associated 
volume overload, prompt myocyte lengthening, resistance training (wrestling, weight 
lifting), which is associated with an intermittent pressure overload, drives mainly to 
thickening of myocytes2. 
Until recently, cardiomyocyte hypertrophy was thought to be the only mean by which 
the heart increased its size, which was in line with the paradigm that heart was a post-
mitotic organ without any renewal potential. However, nowadays’ current evidence 
indicates that human myocardium is capable of, at least in part, renovate itself by new 
cardiomyocyte formation13. Actually, if it was not this self-renewing capacity, the heart 
would lose most of its mass in few decades11. Furthermore, increased levels of division 
markers, along with a rise in the number of cardiomyocytes, has already been 
documented in mice following the application of endurance exercise protocols18, 22. 
Interestingly, the increase in the number of cardiomyocytes was positively related with 
the intensity of physical exercise the rats have been exposed to22. Therefore, it seems 
that the regenerative capacity of myocardium is enhanced by physical activity. 
6 
 
Another possible mechanism by which the heart can increase its mass is through a drop 
in apoptotic rate. Indeed, several studies point in this direction. Endurance exercise has 
been found to attenuate the rise in Bax/Bcl-2 ratio seen with ageing. Consequently there 
is a decrease in the activation of caspase-9 and 3 and DNA fragmentation, which is 
reflected in the superior number of myocytes per area observed in old exercised rats 
compared with sedentary ones4. On the other hand, it was also demonstrated a rise in the 
levels of heat shock protein 70 (HSP70), known to inhibit apoptosis, in the ventricles of 
exercised mice7. At last but not the least, an improved telomerase activity was observed 
in mice exposed to endurance exercise, thereby protecting myocytes from senescence 
and apoptosis. This was found already after 21 days of exercise, even before 
physiological hypertrophy has been documented8. Furthermore, in studies using obese 
rats, endurance exercise was also shown to decrease the number of apoptotic 
cardiomyocytes23, 24 and reverse the architectural changes observed to occur in 
association with obesity23. 
 
Molecular mechanisms 
IGF-1R/PI3K/Akt pathway. The IGF-1R/PI3K/Akt pathway has been extensively 
studied and is seen as the hallmark of physiological hypertrophy20, 25, 26. In fact, the 
nature of myocardial adaptation to increased workload (physiological vs. pathological) 
begins to differentiate already at the growth factor and receptor level – while the 
activation of G-protein coupled receptors by adrenergic stimuli results in pathological 
adaptation of myocardium27, in the presence of physiological stimuli such as physical 
exercise it is the insulin-like growth factor I (IGF-1) acting over its receptor (IGF-1R) 
and triggering the beneficial adaptations described above25-27. 
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In one study using rats, it was shown that swimming training increased the IGF-1 
mRNA after 2 and 6 weeks of exercise28. These findings are compatible with the work 
of Serneri et al. that accessed the concentration of this growth factor in coronary sinus 
and concluded that it was significantly bigger in athletes than in controls29. The 
importance of the pair IGF-1/IGF-1R was further highlighted by knock-out studies in 
which the deletion of IGF-1R in mice attenuated the cardiac hypertrophy seen in 
controls after swimming training20. On the other hand, the overexpression of IGF-1R 
was associated with a proportional increase in the chamber size and wall thickness of 
heart, without any histologic signs of cardiomyopathy, what was also reflected in the 
enhanced systolic function of transgenic IGF-1R animals25. 
IGF-1R is a tyrosine kinase receptor which once stimulated by its ligand phosphorylates 
and activates phosphatidylinositol 3-kinase (PI3K)30. PI3Ks are a family of ubiquitous 
expressed lipid kinases, which are essential for a wide range of biological processes in 
several different types of tissues27. Class-I PI3K phosphorylates phosphatidylinositol-
4,5-bisphosphate to generate phosphatidylinositol-3,4,5-trisphosphate, which in turn 
acts as second messenger to activate Akt. Class-IA PI3K is activated by growth factor 
receptors, such as IGF-1R, while class-IB PI3K is activated by G-protein coupled 
receptors27. The importance of class-IA PI3K activity for the development of 
physiological hypertrophy was well documented by studies in which mice lacking either 
the catalytic or regulatory subunit of this kinase failed to show physiological 
hypertrophy25-27. However, the same didn’t happen when in the presence of a 
pathological stimulus, since even in the absence of the catalytic subunit of class-IA 
PI3K, pressure overload successfully induced pathological hypertrophy26. 
The downstream effector of the IGF-1R/PI3K/Akt pathway is the serine-threonine 
kinase Akt, also known as protein kinase B (PKB). There have been identified 3 
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isoforms of this kinase (Akt1, 2 and 3), and despite their high degree of homology, their 
expression varies among different tissues31. Data suggests that the most important 
isoform in cardiac physiology is Akt119, 31. As noted above, PI3K plays a key role in the 
activation of Akt through generation of phosphatidylinositol-3,4,5-trisphosphate. PTEN 
has the opposite effect, and thus decreases the activation of Akt31. Akt phosphorylates 
several different targets, which implicates it in a variety of biological processes31. The 
importance of Akt for the development of physiological hypertrophy is well supported 
by a study in which mice lacking Akt1 failed in achieving the degree of cardiac 
adaptation seen in their control littermates after a program of swimming training19. In 
addition, this importance is further reinforced by the evidence that overexpression of 
Akt causes cardiac hypertrophy both at the molecular and histological level, without any 
parallel increase in the collagen content of the heart. 
Downstream targets. The mammalian target of rapamycin (mTOR) works as an 
important effector that controls protein synthesis, promoting cellular growth. This is one 
of the downstream targets of Akt, which phosphorylates and inactivates the product of 
tuberous sclerosis gene 2 (TSC2). Doing so, Akt counteracts the inhibition that TSC2 
exerts over mTOR, thereby enhancing its growth promoting effect19. This effect is 
mediated by the phosphorylation of the ribosomal S6 kinase (S6K), that once activated 
phosphorylates and activates the ribosomal protein S632. In addition, the translation 
initiation factor-4E binding protein-1 (4E-BP1) sees its activity increased by mTOR6. 
The net effect is an increased protein synthesis, with consequent cellular hypertrophy6. 
The facts that mice lacking Akt1 showed lower levels of phosphorylated S6K and S6 
after exercise training19 and that overexpression of IGF-1R was associated with an 
increase in phosphorylated S6K25 highlight the importance of the IGF-1R/PI3K/Akt 
pathway for the induction of this system. However, the absence of S6K did not 
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attenuate cardiac physiological hypertrophy when mice were subjected to an exercise 
protocol, which suggests that, while important, S6K is not essential for the development 
of physiological hypertrophy32. 
Another mean by which Akt induces myocyte hypertrophy is by inactivation of 
glycogen synthase kinase-3 beta (GSK-3β)19. GSK-3β phosphorylates and inactivates 
the transcription factor GATA-4, thereby impairing protein synthesis33. Indeed, 
increased levels of the inactive phosphorylated form of GSK-3β were detected in mice 
overexpressing Akt, which reflected in the bigger accumulation of GATA-4 in 
cardiomyocytes’ nuclei30. Once in the nucleus, GATA-4 regulates the expression of a 
variety of cardiac genes related with myocardium hypertrophy33. Moreover, GATA-4 
has also been connected to myocyte proliferation in zebrafish34 
Besides GATA-4, several other transcription factors have been associated to 
cardiomyocytes hypertrophy33. One of the identified transcription factors was C/EBPβ, 
whose expression was found to be reduced after exercise training. Interestingly, that fall 
was secondary to a higher Akt1 activity, and resulted in a reduction of the repressive 
effect that C/EBPβ has over the serum response factor (SRF). SRF is also a transcription 
factor that, among others, promotes the expression of GATA-4. Another downstream 
target negatively regulated by C/EBPβ is the CBP/p300-interacting transactivator with 
ED-rich carboxy-terminal domain 4 (CITED4). In fact, CITED4 was markedly 
increased in cardiomyocytes and induced its proliferation, as reflected by an increase in 
the number of cells18. 
 
The role of microRNAs 
MicroRNAs (miRNA) are a class of recently discovered small molecules, each 
composed of a noncoding sequence of nearly 22 nucleotides, which can modulate gene 
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expression by destroying or repressing the translation of a target RNA. Each miRNA 
molecule can target more than a different mRNA, and each mRNA can be targeted by 
more than a different miRNA, which provides a fine control of gene expression35. Some 
miRNAs have already been identified that are known to play important roles in cardiac 
development. Namely, miRNA-1 and miRNA-133 are of uttermost importance in 
cardiac development by regulating the proliferation and differentiation of 
cardiomyocytes36. The role of miRNA-1 and miRNA-133 in adult heart is less certain, 
but both pathological and physiological hypertrophic stimuli decrease the expression of 
both miRNAs, which suggests an inverse correlation between miRNA-1 and miRNA-
133 and myocardium hypertrophy37. 
In an attempt to identify miRNAs regulated by PI3K, Lin et al. found that mice 
expressing constitutively active PI3K (caPI3K) expressed lower levels of miRNA-222, 
miRNA-34a and miRNA-210 as opposed with controls. Moreover, although the levels 
of these miRNAs increased after myocardial infarction, they remained significantly 
lower in the group expressing caPI3K, and this was reflected in the improved cardiac 
function shown in this group38. Another miRNA that has been shown to be related with 
physiological hypertrophy following a swim training programme was miRNA-29c. 
However, unlike the former, miRNA-29c levels were upregulated after a programme of 
several weeks of physical exercise. The consequence was a downregulation in the 
expression of COLIAI and COLIIIAI, with a decrease of total left ventricle collagen 
content and improved ventricular compliance39. 
 
Endogenous Cardiac Stem Cells 
As described above, the heart harbours a pool of endogenous cardiac stem cells (eCSC). 
The fact that exercised animals’ hearts have shown evidence of new cardiomyocytes 
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formation raises a question – what is the relationship between physical exercise and 
eCSC?  
Some studies exist that try to answer this question. In one of them, the number of c-
Kitpos eCSC was found to be increased in exercised rats in comparison with controls22. 
Also the IGF-1R/PI3K/Akt pathway has been connected with eCSC. In this field, 
current evidence points to a positive correlation between the activation of this pathway 
and the activation and proliferation of eCSC22, 40. Moreover, IGF-1 overexpression 
increased the activity of telomerase, which resulted in a delay in eCSC senescence41. 
Therefore, if the activation of IGF-1R/PI3K/Akt fosters the activation and proliferation 
of eCSC, and if physical exercise promotes the activation of the IGF-1R/PI3K/Akt 
signalling pathway, so it is reasonable to hypothesize that physical exercise is an 
effective trigger of eCSC activation and consequent cardiac regeneration. 
 
Clinical insights 
So far, the only available therapeutic options aim to block the progression on the heart 
disease38. However, as noted above, the last decade brought crescent scientific evidence 
that supports the possibility of exploring new therapeutic approaches that can improve 
the function of the failing heart, thereby improving the quality of life of millions of 
people suffering from cardiac pathology. 
IGF-1R/PI3K/Akt pathway. As stated above, the IGF-1R/PI3K/Akt pathway is the 
central core of physiological hypertrophy. In fact, some studies have already been 
performed in the setting of myocardial infarction that showed a reduction in cardiac 
fibrosis, cardiomyocytes apoptosis and infarction size, as well as better systolic and 
diastolic function, following the administration of IGF-142, 43. Furthermore, in animals 
subjected to myocardial infarction, the treatment with an association of IGF-1 and 
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hepatocyte growth factor (HGF) fostered eCSC activation with consequent cardiac 
regeneration40, 44, 45. Interestingly, this was observed along with increased expression of 
GATA-444 which, as described above, seems to have a role in physiological 
hypertrophy induced by physical exercise. 
microRNAs. The discovery of miRNAs has brought a new biological target for future 
therapies. Actually, today is already possible either to increase the expression, using 
vectors46, or antagonize specific miRNAs using ‘antagomirs’, which are cholesterol-
associated RNAs that block the action of miRNAs over their targets47. The expression 
of miRNA-34a, aforementioned to be decreased in the cardiomyocytes of mice 
expressing caPI3K, has been shown to rise in the ageing heart and following myocardial 
infarction. Interestingly, using antigomir against miRNA-34a it was possible to observe 
a drop in cell death and cardiac fibrosis, and consequent improvement in contractile 
function in mice subjected to myocardial infarction48. Another miRNA described above 
as being negatively correlated with PI3K activity was miRNA-210. By those findings, it 
would be reasonable to think that a decrease in the expression of this miRNA would be 
beneficial. However, other studies found that miRNA-210, whose expression is 
upregulated under hypoxic conditions49, is actually beneficial in the setting of 
myocardial infarction by significantly inducing angiogenesis and decreasing myocytes’ 
apoptotic rate, thereby contributing for a more favourable ventricular remodelling and 
cardiac function46. 
Cell therapy. The first attempts to regenerate myocardial tissue have been done through 
transplant of stem cells from other origins than the heart50, 51. Although animal studies 
have provided exciting results, several clinical trials in humans where already 
performed and showed only modest, if any, improvement in cardiac function50. 
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Therefore, new approaches are needed in order to make this type of therapy more 
effective. 
One of the first questions to be answered is which type of cells suits better for cell-
based therapy. The discovery of a pool of resident cardiac stem cells has opened a new 
window regarding the regenerative potential of this organ, which can be further 
explored either as a therapeutic tool or target. Indeed, a phase 1 clinical trial has 
documented significant improvements in both the ejection fraction and infarct size in 
patients that received autologous cardiac stem cells therapy compared with controls. 
Furthermore, the safety of the treatment was absolute, with no adverse effects registered 
in any of the treated patients52. 
The pool of cardiac stem cells is complex and comprises cells with different capacity to 
replicate and form mature myocytes and blood vessels. In an attempt to better 
characterize those different cellular populations, D’Amario et al. concluded that cardiac 
stem cells expressing IGF-1R were younger and had a better replicative reserve, as 
opposed with cells expressing IGF-2R and AT1R. Moreover, cells expressing IGF-1R 
were capable of secreting both IGF-1 and IGF-2, the latter being responsible for the 
induction of myocyte differentiation. The superiority of IGF-1R expressing cardiac stem 
cells was further confirmed by the greater degree of cardiac recovery after the transplant 
of these cells into hearts of rats subjected to myocardial infarction53. 
Besides the choice of the ideal cell, other strategies can be taken to maximize the 
beneficial effects of cell therapy. Interestingly, the combination of cardiac stem cells 
administration and nanofibers containing IGF-1 resulted in a higher myocardial 
recovery after ischemia when compared with each therapy alone54. 
 
Discussion 
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In the last decade several steps have been taken in order to open new lines of 
investigation regarding new therapeutic strategies. Maybe the biggest advances have 
been done in the field of cell therapy, with some clinical trials already in progress. 
However, as stated above, there is also growing expectation about miRNAs and its 
manipulation. 
The central role that the IGF-1R/PI3K/Akt has in the development of physiological 
hypertrophy has also triggered attempts to modulate this signalling system, namely 
through the therapy with IGF-1. In fact, the results obtained with IGF-1 administration 
in animal models of myocardial infarction were encouraging42, 43. However, this 
signalling pathway is present in a wide range of cell types and because of that systemic 
administration of this growth factor can have diffuse effects and result in the 
progression of occult neoplasms31. 
Concerning cell therapy, some obstacles have been raised regarding the type of cells 
that better fulfil the requirements for the success of this therapeutic approach. By one 
side, the application of cells from other origins than the heart has shown disappointing 
results. Among the causes advanced for this is the source and inadequate preparation of 
the cells, as well as the timing and mode of cell delivery. On the other side, it is 
believed that embryonic stem cells are the ones that have the greatest potential to be 
successful. However, to the risk of teratoma formation and immunogenic 
incompatibilities that the use of embryonic stem cells entails, we still have to add the 
ethical issues50. Finally, it appears that autologous cardiac stem cells transplantation 
may be the best approach, as has been shown by a recent phase 1 clinical trial52. Still, 
more research is needed to find new strategies that can increase the feasibility and 
effectiveness of cell therapy. 
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The discovery of miRNAs has provided a new overview of cellular regulation 
mechanisms. In addition, it represents another process where it is possible to act to 
change the fate of diseased heart. Currently, it is already clear that different miRNAs are 
important in both the heart development and pathology55. Furthermore, some studies 
performed in animals were successful in improving the pattern of cardiac remodelling 
after myocardial infarction46, 48. Nevertheless, miRNAs represent a class of molecules 
that exerts a very delicate control of specific genes at a post-transcriptional level55. 
Consequently, it is critical to better understand the function of each specific miRNA in 
the heart’s physiology and pathology, and only after it will be possible to delineate the 
best plans to take all the potential from this promising area. 
Heart diseases, namely those of ischemic cause, are a major source of morbidity and 
mortality worldwide51. Despite the improvement that the development of several classes 
of drugs have brought to the prognostic of these patients, advances are need so that it 
can be possible to further decrease the burden of disease of cardiac pathologies. 
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Figure legends 
Figure 1 – IGF-1R/PI3K/Akt signalling pathway and downstream targets. Arrows mean 
activation; arrows with a cross mean inhibition; C/EBPB – C/EBPβ; GSK-3B – GSK-
3β. For more details consult the text. 
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